NeuBase Therapeutics (NBSE)
(Delayed Data from NSDQ)
$0.38 USD
0.00 (0.00%)
Updated May 10, 2024 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
NeuBase Therapeutics, Inc. [NBSE]
Reports for Purchase
Showing records 1 - 20 ( 20 total )
Company: NeuBase Therapeutics, Inc.
Industry: Medical - Drugs
Company: NeuBase Therapeutics, Inc.
Industry: Medical - Drugs
F3Q22 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: NeuBase Therapeutics, Inc.
Industry: Medical - Drugs
DM1 Preclinical Data Presented; F2Q22 Financials; Lowering PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: NeuBase Therapeutics, Inc.
Industry: Medical - Drugs
F2021 Financial Results; Multiple Catalysts Approaching; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: NeuBase Therapeutics, Inc.
Industry: Medical - Drugs
Company: NeuBase Therapeutics, Inc.
Industry: Medical - Drugs
Operational Runway Into 2023; F3Q21 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: NeuBase Therapeutics, Inc.
Industry: Medical - Drugs
R&D Day Highlights Demonstrate Platform Breadth; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: NeuBase Therapeutics, Inc.
Industry: Medical - Drugs
Balance Sheet Strengthened; F2Q21 Financials; Lowering PT to $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: NeuBase Therapeutics, Inc.
Industry: Medical - Drugs
F1Q21 Financial Results; Underrated Platform; Raising PT to $18
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: NeuBase Therapeutics, Inc.
Industry: Medical - Drugs
F2020 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: NeuBase Therapeutics, Inc.
Industry: Medical - Drugs
Seminal Preclinical Data Presented on Lead Program; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: NeuBase Therapeutics, Inc.
Industry: Medical - Drugs
F3Q20 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: NeuBase Therapeutics, Inc.
Industry: Medical - Drugs
Company: NeuBase Therapeutics, Inc.
Industry: Medical - Drugs
Equity Financing Complete; Runway Lengthened; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: NeuBase Therapeutics, Inc.
Industry: Medical - Drugs
Highly Promising Preclinical Data Hint at Disruptive Potential; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: NeuBase Therapeutics, Inc.
Industry: Medical - Drugs
Delayed Quarterly Filing; Audit Firm Change; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: NeuBase Therapeutics, Inc.
Industry: Medical - Drugs
Vera Therapeutics Scaffold Acquisition Expands Platform Scope; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: NeuBase Therapeutics, Inc.
Industry: Medical - Drugs
Anticipating Near-Term Progress; Raising PT to $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: NeuBase Therapeutics, Inc.
Industry: Medical - Drugs
Recent Sector Developments Bode Well; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: NeuBase Therapeutics, Inc.
Industry: Medical - Drugs
Addressing Unmet Needs in Neurology and More; Initiating at Buy and $14 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
|